The people who need injectable HIV drugs most are the ones who can’t get them, BHIVA told
Long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression
Adolescents and women who experience violence more likely to get HIV and less likely to control it
Better PrEP retention strategies are needed, as increasing numbers of ex-PrEP users are diagnosed with HIV
HIV treatment adherence may be another casualty of climate change
Antidepressants improve ART adherence and quality of life in HIV-positive men with depression
Four in ten PrEP recipients stop taking it within six months, global meta-analysis reveals
Medical mistrust is linked to discrimination, poor care engagement, and low adherence among Black adults in the US
Study shows Biktarvy for PEP has fewer side effects and better completion rates
